Principal Investigator
Dr. Geno MarcoviciPhD, DABAAHP
Dr. Geno Marcovici is the founder and principal investigator of Continuum Innovative, and serves concurrently as Chief Scientific Officer of Advanced Restoration Technologies, Inc. and TrichoCyte LLC. Across more than thirty years of sustained scientific inquiry, his work has consistently bridged rigorous academic investigation with real-world translational application.
His earliest published contribution — the first randomized, double-blind, placebo-controlled trial to demonstrate efficacy of a botanically derived 5-alpha-reductase inhibitor in androgenetic alopecia (2002) — established a methodological and mechanistic foundation that subsequent investigators have built upon for more than two decades. Later work, conducted in active collaboration with the State University of New York's Center for Functional Genomics, extended this thesis into the molecular domain by demonstrating measurable suppression of LPS-activated inflammatory gene expression in human keratinocytes.
More recent investigation has integrated nanotechnology-enabled delivery — specifically β-cyclodextrin inclusion complexes — into clinically observable follicular response, culminating in the TrichoCyte® formulation platform and its 2020 publication in Cosmetics (MDPI).
That trajectory continues into the present. In 2025, in collaboration with CryoConcepts LP, Dr. Marcovici co-authored a first-in-field innovative-practice report in the Journal of Complementary Research and Alternative Medicine describing the use of a cryo-chilled, CO₂-bolstered delivery device to amplify the nano-botanical platform in advanced-stage androgenetic alopecia. Phenotypic reversal observed by day 90 was sufficient to terminate the planned 270-day protocol 180 days ahead of schedule — re-establishing the program at the leading edge of follicular regenerative medicine. The full arc — from hypothesis through molecular mechanism through clinical translation and now device-augmented amplification — defines the current scientific direction of Continuum Innovative.
Career & Leadership
- 1993 — PresentFounder & Chief Scientific OfficerAdvanced Restoration Technologies, Inc. (HairGenesis®)
Founded the parent research and development organization behind the HairGenesis® brand — among the first botanically derived hair restoration platforms validated under formal randomized controlled trial conditions.
- 2019 — PresentChief Scientific OfficerTrichoCyte LLC
Direction of the TrichoCyte® β-cyclodextrin inclusion-complex platform — a nanotechnology-enabled topical delivery system for follicular bioactives.
- PresentFounder & Principal InvestigatorContinuum Innovative | Life Sciences Division
Hypothesis-driven research entity investigating biological stability — how it is maintained, lost, and restored — using the hair follicle as a uniquely accessible regenerative organ system.
Areas of Expertise
Dr. Marcovici's expertise extends well beyond any single mechanism-of-action. Below is the broader landscape — board credentialing, cross-disciplinary peer review, regenerative medicine, and translational formulation science — alongside the androgen-driven follicular biology for which his published program is best known.
Board Certification & Credentialing
- Board-certified in Regenerative Medicine — continuously credentialed for more than 11 years
- Doctoral training in biomedical sciences with formal post-doctoral research experience
- Decades of bench-to-bedside translational practice across multiple therapeutic areas
Peer Review — Cross-Disciplinary
- Invited manuscript reviewer for international journals across cardiology, pulmonology, dermatology, endocrinology, psychiatry, oncology, and complementary/integrative medicine
- Editorial board and ad-hoc reviewer roles spanning both basic-science and clinical literature
- Routine review of randomized controlled trial design, mechanistic in-vitro work, and translational case series
Regenerative & Translational Medicine
- Systems-biology approach to tissue stability — how it is maintained, lost, and restored
- Intracrine signaling, stem/progenitor biology, and the regenerative micro-environment
- Translational formulation science: concept → bench → clinic → worldwide commercialization
Hair Biology & Androgen-Driven Disease
- Androgenetic alopecia — pathogenesis, hormonal drivers, and rational therapeutic design
- 5α-reductase inhibition (synthetic and botanically derived) and androgen-receptor signaling
- Follicular inflammation, cytokine biology, and genomic profiling of inflammatory pathways
Drug Delivery & Formulation Innovation
- β-cyclodextrin inclusion complexes and nano-enabled topical delivery
- Concomitant oral + topical regimen design for follicular and systemic targets
- Device-augmented delivery — including cryo-carboxy amplification of botanical actives
Intellectual Property & Commercial Translation
- Inventor on multiple issued U.S. and international patents
- Formulation, clinical evaluation, regulatory positioning, and global brand development
- Strategic and scientific advisor to industry partners and clinical practices
Selected Peer-Reviewed Publications
A representative selection across the arc of investigation. A complete record — including review activity — is maintained on ORCID .
- 2002Prager N, Bickett K, French N, Marcovici G.A randomized, double-blind, placebo-controlled study to determine the effectiveness of botanically derived inhibitors of 5-alpha-reductase in the treatment of androgenetic alopecia.J Altern Complement Med · PMID: 12006122
- 2011Chittur S, Parr B, Marcovici G.Inhibition of inflammatory gene expression in keratinocytes using a composition containing carnitine, thioctic acid, and Serenoa repens extract.Evid Based Complement Alternat Med (eCAM) · PMC3137880
- 2016Marcovici G, Li YC, Mouser G, Wang J, Chen L.Blockade of androgen markers using a novel betasitosterol, thioctic acid and carnitine-containing compound in prostate and hair follicle cell-based assays.Phytotherapy Research · PMID: 26990224
- 2020Marcovici G, Bauman A.An uncontrolled case series using a botanically derived, β-cyclodextrin inclusion complex in two androgenetic-alopecia-affected male subjects.Cosmetics (MDPI) · DOI: 10.3390/cosmetics7030065
- 2025Niedbala S, Campbell E, Young L, Marcovici G.An uncontrolled innovative test of cryo-chilled carbon dioxide as a novel amplification of a nano-botanical multi-acting therapy in advanced-stage androgenetic alopecia.J Complement Res Altern Med 2(1):1–9 · First-in-field cryo-carboxy × nano-botanical platform
Education & Credentialing
- PhD — biomedical research training underpinning three decades of original investigation.
- DABAAHP — Diplomate, American Board of Anti-Aging Health Practitioners.
- Active peer reviewer for journals across Nature Portfolio, Springer, Elsevier, Wiley, and MDPI — with 100+ manuscripts reviewed across more than 50 medical sub-specialty journals.
Intellectual Property
- HairGenesis® — USPTO Reg. No. 3,567,177.
- Trichoceutical® — USPTO Reg. No. 3,935,889.
- TrichoCyte® β-cyclodextrin inclusion-complex delivery platform — proprietary formulation system.
- Additional pending and issued IP covering hair restoration formulations and delivery technologies.
Active USPTO Provisional Filings
Provisional applications presently in force
- Progressive Autoimmune Loss of Privilege (USPTO 64/065,059) — Systems and methods for the preservation of follicular territorial integrity via restoration of immune privilege and suppression of ectopic antigen presentation.
- Intracrine Structure–Function Dynamics (USPTO 64/063,263) — Systems-architecture modulation of intracrine androgen metabolism and pleiotropic signaling within the hair-follicle micro-organ.
- Coordinated Multi-Nodal Stabilization (USPTO 64/069,570) — Coordinated multi-nodal stabilization of follicular phenotype architecture through integrated pleiotropic signaling modulation.
- Senescence Biology (USPTO 64/073,264) — Methods and compositions for preserving or restoring regenerative competence in senescent scalp hair follicles.
See the Intellectual Property page for full innovation themes and prosecution context.
Three decades of inquiry. One continuous body of work bridging discovery, mechanism, and translation.